Kimberley S. Mak, MD, MPH
Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Radiation Oncology

MD, Harvard Medical School
MPH, Harvard School of Public Health
AB, Harvard College



Kimberley S. Mak, MD, MPH, is an Associate Professor of Radiation Oncology at the Chobanian and Avedisian School of Medicine and its affiliate Boston Medical Center (BMC). She received her MPH from Harvard School of Public Health, MD from Harvard Medical School, and AB summa cum laude in Biochemical Sciences from Harvard College. Dr. Mak completed an internship in Internal Medicine at Brigham and Women's Hospital, followed by residency in the Harvard Radiation Oncology Program, training at Massachusetts General Hospital, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Children's Hospital of Boston, and BMC. Dr. Mak has board certification in Radiation Oncology by the American Board of Radiology.

Dr. Mak's specialties include thoracic, gastrointestinal, breast, and musculoskeletal malignancies. She leads the Cyberknife® radiosurgery program for thoracic and gastrointestinal malignancies. She speaks English and Cantonese. As Clinical Director of the Department of Radiation Oncology at BMC, she spearheaded quality improvement efforts leading to BMC becoming the first site in Massachusetts to achieve accreditation through the American Society for Radiation Oncology (ASTRO) Accreditation Program for Excellence (APEx). She further analyzes quality metrics as Cancer Liaison Physician for the BMC Cancer Care Committee/American College of Surgeons Commission on Cancer.

Dr. Mak's research interests include patient-reported outcomes including quality of life and treatment toxicities; disparity outcomes research; intensity-modulated and image-guided radiotherapy; CyberKnife® stereotactic radiotherapy; translational research; and functional imaging in radiotherapy. She has training and experience in biostatistics, epidemiology, decision analysis, meta-analysis, clinical trial design, and molecular and cell biology laboratory work. Dr. Mak serves on multiple committees for ASTRO and the international cooperative research group, NRG Oncology. She has contributed her expertise in working groups for the National Quality Forum, Lung Cancer 360 and International Consortium for Health Outcomes Measurement.

Member
Boston University
BU-BMC Cancer Center


Boston Medical Center


VA Boston Healthcare System





Improving PRO Interpretation at the Individual Level for Patients with Cancer using Conversational Agents and Data Visualization
03/01/2023 - 02/28/2025 (Subcontract PI)
PI: Kimberley S. Mak, MD, MPH
Tufts Medical Center NIH NCI
7R01CA271145-02


Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Mak KS, Scannell Bryan M, Dignam JJ, Shipley WU, Lin Y, Peters CA, Gore EM, Rosenthal SA, Zeitzer KL, D'Souza DP, Horwitz EM, Pisansky TM, Maier JM, Chafe SM, Robin TP, Roach M, Tran PT, Souhami L, Michalski JM, Hartford AC, Feng FY, Sandler HM, Efstathiou JA. Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202. Eur Urol Focus. 2024 Mar; 10(2):271-278. PMID: 38307806; PMCID: PMC11257781; DOI: 10.1016/j.euf.2024.01.008;
     
  2. Dudipala H, Burns L, Jani CT, Radwan A, Al Omari O, Patel M, Kilic S, Zhao J, Mak K, Suzuki K, Tapan U. Disparities in Lung Cancer Clinical Trial Discussion and Enrollment at a Safety Net Hospital. Community Health Equity Res Policy. 2023 Dec 12; 2752535X231221394.View Related Profiles. PMID: 38087807
     
  3. Qureshi MM, Lin Y, Moeller AR, Yan SX, Dyer MA, Suzuki K, Everett P, Litle V, Truong MT, Mak KS. Change in stage after neoadjuvant chemoradiation is associated with survival in patients with esophageal cancer. J Surg Oncol. 2023 Oct; 128(5):781-789.View Related Profiles. PMID: 37288789
     
  4. Qureshi MM, Kam A, Suzuki K, Litle V, Tapan U, Balasubramaniyan R, Dyer MA, Truong MT, Mak KS. Association between hospital safety-net burden and receipt of trimodality therapy and survival for patients with esophageal cancer. Surgery. 2023 May; 173(5):1153-1161.View Related Profiles. PMID: 36774317
     
  5. Oladeru OT, Lam CM, Qureshi MM, Hirsch AE, Mak KS, Dyer MA, Truong MT. Inequalities in Cancer Stage at Diagnosis Among Incarcerated Individuals Undergoing Radiation Therapy at a Large Safety-Net Hospital. Int J Radiat Oncol Biol Phys. 2023 May 01; 116(1):194-198.View Related Profiles. PMID: 36758643
     
  6. Asokan S, Pavesi F, Bains A, Qureshi MM, Shetty S, Singh S, Mak KS, Litle VR, Suzuki K. Frailty Index is Associated with Treatment Decisions for Stage I Non-Small Cell Lung Cancer at a High-Burden Safety-Net Hospital. Clin Lung Cancer. 2023 Mar; 24(2):153-164.View Related Profiles. PMID: 36641324
     
  7. Siddiqi N, Pan G, Liu A, Lin Y, Jenkins K, Zhao J, Mak K, Tapan U, Suzuki K. Timeliness of Lung Cancer Care From the Point of Suspicious Image at an Urban Safety Net Hospital. Clin Lung Cancer. 2023 Mar; 24(2):e87-e93.View Related Profiles. PMID: 36642641
     
  8. Liu A, Siddiqi N, Tapan U, Mak KS, Steiling KA, Suzuki K. Black Race Remains Associated with Lower Eligibility for Screening Using 2021 US Preventive Services Task Force Recommendations Among Lung Cancer Patients at an Urban Safety Net Hospital. J Racial Ethn Health Disparities. 2023 Dec; 10(6):2836-2843.View Related Profiles. PMID: 36441493
     
  9. Lee MH, Qureshi MM, Suzuki K, Everett P, Tapan U, Mak KS. Small cell lung cancer in young patients: trends in sociodemographic factors, diagnosis, treatment, and survival. J Thorac Dis. 2022 Aug; 14(8):2880-2893.View Related Profiles. PMID: 36071763; PMCID: PMC9442513; DOI: 10.21037/jtd-22-210;
     
  10. Matthews BJ, Qureshi MM, Fiascone SJ, Nitschmann CC, Oladeru OT, Truong MT, Hirsch AE, Mak KS, Dyer MA. Racial disparities in non-recommendation of adjuvant chemotherapy in stage II-III ovarian cancer. Gynecol Oncol. 2022 01; 164(1):27-33.View Related Profiles. PMID: 34785030; PMCID: PMC8711036; DOI: 10.1016/j.ygyno.2021.10.028;
     
Showing 10 of 44 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 44 publications over 14 distinct years, with a maximum of 8 publications in 2021

YearPublications
20051
20081
20102
20143
20152
20165
20176
20182
20192
20203
20218
20224
20234
20241


Higher Radiation Doses Tied To Increased Longevity In Node-Negative Lung Cancer

Reuters Health via M.D./alert 4/30/2019

2008-2009 Howard Hughes Medical Institute: Medical Student Research Training Fellowship
2005 Harvard College: Phi Beta Kappa
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Anal cancer
Bile duct cancer
Colorectal cancer
Cyberknife radiosurgery
Disparity outcomes research
Esophageal cancer
Gastric cancer
Gastrointestinal malignancies
Image-guided radiotherapy
Intensity-modulated radiotherapy
Liver cancer
Lung cancer
Outcomes research
Pancreatic cancer
Patient-reported outcomes
Radiation oncology
Stereotactic body radiotherapy
Stereotactic radiosurgery
Thoracic malignancies
Translational research

Mentorship for students interested in oncology, radiation oncology, lung cancer, gastrointestinal cancer, gynecologic cancers, patient-reported outcomes including quality of life, disparities outcomes research, and outcomes research.

Available to Mentor as: (Review Mentor Role Definitions):
  • Career Mentor
  • Project Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')

818 Harrison Ave
Boston MA 02118
Google Map

617.638.7070
Download vCard

Mak's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
See all (221) concept(s)
_
Media Mentions
_
Co-Authors
See all (21) people
_
Similar People
See all (60) people
_
Same Department
Search Department